country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-P992535

Copy Link Print Information

JANX-007

JANX-007 is a tumor protease-activated anti-PSMA x CD3 bispecific T cell engager (BiTE). After JANX-007 is cleaved by tumor-specific proteases in the tumor microenvironment to remove the mask, CD3 is exposed, recruiting T cells to kill PSMA-positive tumor cells, and the activated and released TCE fragment can be rapidly cleared. JANX-007 can be used in cancer-related research, such as metastatic castration-resistant prostate cancer.

For research use only. We do not sell to patients.

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

JANX-007 Chemical Structure

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Species Reactivity
- In Vitro
- Target
- Conjugated
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Species Reactivity

Human

In Vitro

JANX-007 exerts its function after tumor protease cleavage of the linker sequence removes the mask and albumin-binding domain, thereby mediating tumor cell killing; the activated TCE fragment released from the tumor is designed to be rapidly cleared in circulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

Target

PSMA & CD3

Conjugated

Unconjugated

Application

ELISA, FACS, Functional assay

Chemical Information

SMILES

[JANX-007]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Inhibitory Antibodies User Guide (603 KB)

References

[1]. Zhang J, et al. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Cancers. 2024 Sep 06;16(17):3098.

[2]. Hudson A, et al. A phase 1, first-in-human, dose escalation study of JNJ-80038114, a PSMAxCD3 bispecific antibody, in participants with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology. 2026 Jan 06;96(1):5.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote